Aprazer Healthcare Launched TAFSURE

Posted by

Aprazer Healthcare

September 4, 2025

On May 10, 2019

Aprazer Healthcare Launched TAFSURE (Tenofovir alafenamide ) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan for use in the treatment of HIV/AIDS and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate

Newer

Aprazer tie-up with BDR International

Older Aprazer Healthcare tie up Akums Drugs & Pharmaceuticals Limited

Disclaimer: This medical information is intended only for healthcare professionals in India. The products discussed herein may have different product labeling in other countries. The information within this site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. For full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events, please submit a medical information request. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Any liability for patent infringement is at the buyer's risk. The website does not sell/purchase any medicine.